{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:46:52Z","timestamp":1781059612052,"version":"3.54.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Several studies have described the rapid decline and clearance of hepatitis B surface antigen (HBsAg) in human immunodeficiency virus (HIV)\/hepatitis B virus (HBV) coinfection after initiating combined antiretroviral therapy (cART). Early decline of HBsAg levels is associated with HBsAg seroclearance in the treatment of chronic HBV infection. This study aims to evaluate the HBsAg kinetics and the determinants of early HBsAg decline in patients with HIV\/HBV coinfection during cART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 51 patients with HIV\/HBV coinfection were enrolled from a previously established HIV\/AIDS cohort and followed for a median of 59.5 months after cART initiation. Biochemical tests, virology and immunology assessments were measured longitudinally. The kinetics of HBsAg during cART were analyzed. Soluble programmed death-1 (sPD-1) levels and immune activation markers (CD38 and HLA-DR) were measured at baseline, 1-year and 3-year during treatment. HBsAg response was defined as a decline of more than 0.5 log<jats:sub>10<\/jats:sub> IU\/ml at 6 months from the baseline after initiation of cART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HBsAg declined faster (0.47 log<jats:sub>10<\/jats:sub> IU\/mL) in the first six months and attained a decrease of 1.39 log<jats:sub>10<\/jats:sub> IU\/mL after 5-year therapy. Seventeen (33.3%) participants achieved a decline of more than 0.5 log<jats:sub>10<\/jats:sub> IU\/ml at the first 6 months of cART(HBsAg response) of which five patients achieved HBsAg clearance at a median of 11 months (range: 6-51 months). Multivariate logistic analysis showed the lower baseline CD4<jats:sup>+<\/jats:sup> T cell levels (OR=6.633, <jats:italic>P<\/jats:italic>=0.012) and sPD-1 level (OR=5.389, <jats:italic>P<\/jats:italic>=0.038) were independently associated with HBsAg response after cART initiation. The alanine aminotransferase abnormality rate and HLA-DR expression were significantly higher in patients who achieved HBsAg response than in those who did not achieve HBsAg response after cART initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lower CD4 <jats:sup>+<\/jats:sup> T cells, sPD-1, and immune activation were related to a rapid HBsAg decline in patients with HIV\/HBV-coinfection after the initiation of cART. These findings imply that immune disorders induced by HIV infection may disrupt immune tolerance to HBV, leading to a faster decline in HBsAg levels during coinfection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1178788","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:27:14Z","timestamp":1683091634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV\/HBV coinfection during combined antiretroviral therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaodi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000002386","article-title":"Long-term TDF-inclusive ART and progressive rates of HBsAg loss in HIV-HBV coinfection-lessons for functional HBV cure","volume":"84","author":"Audsley","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2016.10.011","article-title":"Role of HBsAg decline in patients with chronic hepatitis b HBeAg-negative and e genotype treated with pegylated-interferon","volume":"136","author":"Boglione","year":"2016","journal-title":"Antiviral Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/Jvi.02844-06","article-title":"Characterization of hepatitis b virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J. Virol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v13071341","article-title":"Functional cure of hepatitis b virus infection in individuals with HIV-coinfection: a literature review","volume":"13","author":"Boyd","year":"2021","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095870","article-title":"Circulating programmed death-1 as a marker for sustained high hepatitis b viral load and risk of hepatocellular carcinoma","volume":"9","author":"Cheng","year":"2014","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/infdis\/jiz450","article-title":"High rates of hepatitis b virus (HBV) functional cure among human immunodeficiency virus-HBV coinfected patients on antiretroviral therapy in Zambia","volume":"221","author":"Chihota","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00535-022-01874-8","article-title":"Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis b","volume":"57","author":"Chu","year":"2022","journal-title":"J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis b - report from the 2019 EASL-AASLD HBV treatment endpoints conference(double dagger)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis b surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/ajg.2011.253","article-title":"Quantitative hepatitis b surface antigen levels in patients with chronic hepatitis b after 2 years of entecavir treatment","volume":"106","author":"Fung","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis b: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis b infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s12072-022-10411-x","article-title":"Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis b in an international cohort","volume":"16","author":"Hsu","year":"2022","journal-title":"Hepatol. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis b","volume":"224","author":"Hsu","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/apt.16752","article-title":"Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis b","volume":"55","author":"Hu","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac451","article-title":"Hepatitis b-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization","volume":"9","author":"Iannetta","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/jac\/dkw019","article-title":"Alpha-fetoprotein level-dependent early hepatitis b surface antigen decline during entecavir therapy in chronic hepatitis b with hepatitis flare","volume":"71","author":"Jeng","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01023","article-title":"Immunological efficacy of tenofovir disproxil fumarate-containing regimens in patients with HIV-HBV coinfection: a systematic review and meta-analysis","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia Expert opinion on treatment initiation for chronic hepatitis b","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis b infection in people living with human immunodeficiency virus: a systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis b surface antigen and hepatitis b e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis b patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41575-019-0197-8","article-title":"Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection","volume":"16","author":"Liaw","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis b","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis b cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9647","DOI":"10.18632\/aging.204416","article-title":"The pattern and magnitude of T cell subsets reconstitution during ten years of ART with viral suppression in HIV-infected patients","volume":"14","author":"Lu","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis b for special issue","volume":"29","author":"Mak","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jinf.2020.04.037","article-title":"Treatment advantage in HBV\/HIV coinfection compared to HBV monoinfection in a south African cohort","volume":"81","author":"Maponga","year":"2020","journal-title":"J. Infect."},{"key":"B30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/apt.13779","article-title":"Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis b","volume":"44","author":"Marcellin","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","article-title":"Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis b patients under 4-year entecavir therapy","volume":"60","author":"Papatheodoridis","year":"2014","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/jvh.12434","article-title":"Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis b patients treated with tenofovir disoproxil fumarate","volume":"22","author":"Papatheodoridis","year":"2015","journal-title":"J. Viral Hepat"},{"key":"B33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis b surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2011","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis b e antigen-positive chronic hepatitis b using on-treatment hepatitis b surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cis859","article-title":"Close monitoring of hepatitis b surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis b","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1111\/liv.14684","article-title":"Obstacles to HBV functional cure: late presentation in HIV and its impact on HBV seroconversion in HIV\/HBV coinfection","volume":"40","author":"van Bremen","year":"2020","journal-title":"Liver Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype a HBeAg-positive chronic hepatitis b","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int."},{"key":"B39","unstructured":"Hepatitis b2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis b surface antigen decline during 3 years of telbivudine treatment in hepatitis b e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/apt.15732","article-title":"Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis b virus-infected patients with different disease phases and after anti-viral treatment","volume":"51","author":"Xia","year":"2020","journal-title":"Aliment Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.1.20659","article-title":"Prevalence of hepatitis b and c viruses in HIV-positive patients in China: a cross-sectional study","volume":"19","author":"Xie","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/jvh.13212","article-title":"Long-term observation on hepatitis b surface antigen seroclearance in therapy experienced HIV\/HBV co-infected Chinese","volume":"27","author":"Yang","year":"2020","journal-title":"J. Viral Hepat"},{"key":"B44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jvh.13720","article-title":"Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: an opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis b","volume":"29","author":"Yao","year":"2022","journal-title":"J. Viral Hepat"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis b surface antigen loss in hepatitis b Virus\/Human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1182\/blood-2006-09-044826","article-title":"PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors","volume":"109","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jvh.13055","article-title":"Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis b","volume":"26","author":"Zhou","year":"2019","journal-title":"J. Viral Hepat"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/QAD.0000000000002165","article-title":"Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection","volume":"33","author":"Zilber","year":"2019","journal-title":"AIDS"},{"key":"B49","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis b surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B50","year":"2022","journal-title":"HIV"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1178788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:27:18Z","timestamp":1683091638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1178788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":50,"alternative-id":["10.3389\/fcimb.2023.1178788"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1178788","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1178788"}}